MEDIROM Healthcare Technologies Inc. (MRM) carries a Roarable Rating of D (Sell) with 51/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $0.33 (0.00% 1D, market cap $2.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1011 tracked Consumer Discretionary issuers, MRM ranks #536 in composite RQD confidence.
Within the Consumer Discretionary sector (Other Consumer Services), MRM carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, OCG (Oriental Culture Holding LTD) holds a D- grade (42/100 RQD, P/E N/A, ROIC -9.4%, cap $3.1M) and PMAX (Powell Max Limited (Class A)) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $2.0M). Among the 5-stock peer group, MRM leads on earnings multiple (N/A) while OCG leads on capital efficiency (-9.4% ROIC).
For MEDIROM Healthcare Technologies Inc. (MRM), key quantitative strengths include Established market leader in Consumer Discretionary with deep daily trading liquidity. and sector rank #536 in Consumer Discretionary, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL Trailing 12 Months: 0% FCF Margin ($73.0K FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)
While MRM currently carries a cautious 51/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Consumer Discretionary with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.64) and Max Pain ($0.35) forces dealer call-delta covering toward $2.45.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
MEDIROM Healthcare Technologies Inc. (MRM) slipped 0.00% to $0.33, trading at 4% of its 52-week range ($0.25 – $2.33). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Yahoo Finance Singapore report covering MEDIROM Healthcare Technologies Inc. (MRM) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering MEDIROM Healthcare Technologies Inc. (MRM) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering MEDIROM Healthcare Technologies Inc. (MRM) market action, institutional positioning, and fundamental catalysts.
Kalkine report covering MEDIROM Healthcare Technologies Inc. (MRM) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering MEDIROM Healthcare Technologies Inc. (MRM) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering MEDIROM Healthcare Technologies Inc. (MRM) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering MEDIROM Healthcare Technologies Inc. (MRM) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering MEDIROM Healthcare Technologies Inc. (MRM) market action, institutional positioning, and fundamental catalysts.
Gainers Lobo Technologies (NASDAQ:LOBO) stock moved upwards by 8.4% to $0.49 during Thursday's pre-market session. The market value of their outstanding shares is at $6.4 million. E-Home Household Service
US-listed unusual volume stocks include WFF, TGL, MRM, TCRT, DKI, XXII, CCC, HODO, SDST and SXTC, with sharp gains and declines versus 50-day average volume.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MRM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MRM. Explore sector supply chains on /butterfly.
Across 1011 tracked Consumer Discretionary securities in the Roarable RQD universe, MEDIROM Healthcare Technologies Inc. (MRM) ranks #536 by composite RQD confidence (51/100, grade D) and #989 by equity capitalization ($2.6M). Within this direct 5-issuer industry benchmark cohort, MRM leads on earnings valuation at N/A trailing P/E, while OCG leads on capital efficiency and profitability with -9.4% ROIC and 85.7% gross margin. MRM currently leads its immediate peer cohort in composite quantitative strength at 51/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MRM
ACTIVE
MEDIROM Healthcare Technologies Inc. | D | 51/100 | — | — | — | 0.00% | $2.6M | Benchmark Subject |
| OCG Oriental Culture Holding LTD | D- | 42/100 | — | 85.7% | -9.4% | +1.25% | $3.1M | /ocg-vs-mrm → |
| PMAX Powell Max Limited (Class A) | D | 49/100 | — | — | — | +23.45% | $2.0M | /pmax-vs-mrm → |
| EJH E-Home Household Service Holdings Limited | D- | 35/100 | — | 22.4% | — | +1.53% | $4.2M | /ejh-vs-mrm → |
| JWEL Jowell Global Ltd. | D- | 38/100 | — | — | -35.0% | -6.60% | $5.0M | /jwel-vs-mrm → |
MEDIROM Healthcare Technologies Inc. (MRM) operates in Other Consumer Services (Consumer Discretionary) with an equity capitalization of $2.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-03, MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $0.33 (0.00% 1D, market cap $2.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 9/20. Across 1011 tracked Consumer Discretionary issuers, MRM ranks #536 in composite RQD confidence.
Within the Consumer Discretionary sector (Other Consumer Services), MRM carries a Roarable D (51/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, OCG (Oriental Culture Holding LTD) holds a D- grade (42/100 RQD, P/E N/A, ROIC -9.4%, cap $3.1M) and PMAX (Powell Max Limited (Class A)) posts a D grade (49/100 RQD, P/E N/A, ROIC —, cap $2.0M). Among the 5-stock peer group, MRM leads on earnings multiple (N/A) while OCG leads on capital efficiency (-9.4% ROIC).
For MEDIROM Healthcare Technologies Inc. (MRM), key quantitative strengths include Established market leader in Consumer Discretionary with deep daily trading liquidity. and sector rank #536 in Consumer Discretionary, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
MRM last traded at $0.33 (0.00% on volume of 26,221 shares), positioning the stock -48.44% below its 50-day simple moving average ($0.64) and -68.27% below its 200-day simple moving average ($1.04). Across its 52-week range of $0.25 to $2.33, MRM sits at the 3.8% percentile with a 14-day RSI of 26.4 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.37).
MRM scores 51 out of 100, a letter grade of D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine 12/20 (ROIC 0%; FCF yield 0%), Whale 13F Flow 6/20 (institutional accumulation and options positioning), Insider Conviction 9/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 11/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 13/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). The weakest pillars are the cash engine and institutional/insider flow, which together point to limited evidence of cash generation and little visible accumulation. The balance-sheet pillar is the strongest component, which suggests solvency signals are less concerning than earnings and flow signals. For a prospective investor, the rating highlights that any upside thesis would have to rest on catalysts rather than current cash returns, and that the stock's price of $0.35 and market capitalization of $2.7M imply a high-risk, small-capitalization profile.
MEDIROM Healthcare Technologies Inc. Is listed on NASDAQ under the ticker MRM.. — for products sold, customer base, or revenue model.
Per the market data, gross, operating, and net margins are each reported as 0%, and ROIC is reported as 0%. The Forensic Balance Sheet pillar of the Roarable RQD rating reports an Altman Z-Score of 2.5, a Piotroski F-Score of 6/9, and a Debt/Equity ratio of 0.5. Free cash flow yield is reported as 0%.
Supply_chain is NONE, butterfly_links is empty, and proprietary_signals is empty.
Real-time company headlines, analyst actions, and sector developments for MEDIROM Healthcare Technologies Inc. (MRM) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Singapore report covering MEDIROM Healthcare Technologies Inc. (MRM) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering MEDIROM Healthcare Technologies Inc. (MRM) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering MEDIROM Healthcare Technologies Inc. (MRM) market action, institutional positioning, and fundamental catalysts.
Kalkine report covering MEDIROM Healthcare Technologies Inc. (MRM) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering MEDIROM Healthcare Technologies Inc. (MRM) market action, institutional positioning, and fundamental catalysts.
Yahoo! Finance Canada report covering MEDIROM Healthcare Technologies Inc. (MRM) market action, institutional positioning, and fundamental catalysts.
Benzinga report covering MEDIROM Healthcare Technologies Inc. (MRM) market action, institutional positioning, and fundamental catalysts.
TradingKey report covering MEDIROM Healthcare Technologies Inc. (MRM) market action, institutional positioning, and fundamental catalysts.
Long MRM at $0.33 targeting $0.40. The Forensic Balance Sheet pillar scores 13/20 with an Altman Z of 2.5 and Piotroski F of 6/9, indicating solvency signals stronger than the cash engine.. Institutional whale score is 6/20 and the risk/reward vs. the $0.25 52-week low is skewed heavily in favor of bulls.
@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Other Consumer Services. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
Here is the bear case nobody on the bull side wants to address on MRM: ROIC and FCF yield are both 0% and the Whale 13F and Insider pillars score 6/20 and 9/20, indicating weak cash generation and limited accumulation.. At current EV/EBITDA multiples, even a small guidance miss in Other Consumer Services triggers a 12-15% air pocket.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).